Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant candida species

Pediatrics

Volumn 121, Issue 4, 2008, Pages 703-710

  Healy, C Mary ^a,b   Campbell, Judith R ^a,b   Zaccaria, Elena ^a   Baker, Carol J ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Baylor College of Medicin   (United States)

^c Woman's Hospital of Texas   (United States)

Author keywords

Candida infection; Extremely low birth weight; Fluconazole prophylaxis; Neonates; Resistance

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; AMPICILLIN; CASPOFUNGIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CLINDAMYCIN; FLUCONAZOLE; GENTAMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MEROPENEM; METOCLOPRAMIDE; NAFCILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; RIFAMPICIN; TIMENTIN; URSODEOXYCHOLIC ACID; VANCOMYCIN; ANTIFUNGAL AGENT;

AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CHOLESTASIS; COMPARATIVE STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG SAFETY; DRUG TOLERABILITY; EXTREMELY LOW BIRTH WEIGHT; FEMALE; FUNGAL MENINGITIS; FUNGUS ISOLATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; INVASIVE CANDIDIASIS; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR ACCESS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CANDIDIASIS; COHORT ANALYSIS; DRUG EFFECT; FOLLOW UP; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MULTIVARIATE ANALYSIS; MYCOSIS; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUCONAZOLE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MULTIVARIATE ANALYSIS; MYCOSES; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 42949090918     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-1130     Document Type: Article

References (37)

1. Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am. 1988;35(3): 543-563
2. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996;129(1):63-71
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2):285-291
4. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006; 117(5):1680-1687
5. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Do- nowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001; 345(23):1660-1666
6. Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmo-
7. logic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis. 2001;32(7):1018-1023
8. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17(6): 504-508
9. Benjamin DK Jr, DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark RH. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics. 2003;112(3):543-547
10. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J. 2000;19(4):319-324
11. Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J. 2000; 19(9):822-827
12. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth- weight infants with neonatal infection. JAMA. 2004;292(19): 2357-2365
13. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84-92
14. Smith PB, Morgan J, Benjamin DK, et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J. 2007;26(3):197-200
15. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161-189
16. American Academy of Pediatrics. Candidiasis. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:242-246
17. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics. 2001;107(2): 293-298
18. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2004;(1): CD003850
19. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr. 2005;147(2):172-179
20. Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on rate and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr. 2005;147(2):166 -171
21. Manzoni P, Arissio R, Mostert M, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics. 2006;117(1). Available at: www.pediatrics.org/cgi/content/ full/117/1/e22
22. Bertini G, Perugi S, Dani C, et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr. 2005;147(2):162-165
23. Uko S, Soghier LM, Vega M, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics. 2006;117(4):1243-1252
24. Aghai ZH, Mudduluru M, Nakhla TA, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatal. 2006;26(9):550-555
25. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356(24):2483-2495
26. Walsh TJ, Gonzalez CE, Piscitelli S, et al. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol. 2000;38(6):2369-2373
27. Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses. 1994; 37(3-4):127-130
28. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr. 2005;147(2): 135-141
29. Fanaroff AA. Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics. 2006;117(1):214-215
30. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard 2nd ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002. Clinical and Laboratory Standards Institute document M27-A2
31. Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics. 2006;118(6):2359-2364
32. Feja KN, Wu F, Roberts K, et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr. 2005;147(2):156-161
33. Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118(2): 717-722
34. Burwell LA, Kaufman D, Blakely J, Stoll BJ, Fridkin SK. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics. 2006;118(4). Available at: www.pediatrics.org/cgi/ content/full/118/4/e1019
35. Kaufman DA, Gurka MJ, Hazen KC, et al. Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J. 2006;25(8):733-737
36. Yoder BA, Sutton DA, Winter V, Coalson JJ. Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model. Pediatr Infect Dis J. 2004;23(7):687-688
37. Christensen RD, Henry E, Wiedneier SE, Burnett J, Lambert DK. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Peri- natol. 2007;27(5):284-290